Related Experiment Video
Updated: Feb 13, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach
Niamh Coleman1, Malaka Ameratunga1, Juanita Lopez1
1Drug Development Unit, The Royal Marsden Hospital, London, UK.
Abstract:
Over the past decade, precision cancer medicine has driven major advances in the management of advanced solid tumours with the identification and targeting of putative driver aberrations transforming the clinical outcomes across multiple cancer types. Despite pivotal advances in the characterization of genomic landscape of glioblastoma, targeted agents have shown minimal efficacy in clinical trials to date, and patient survival remains poor. Immunotherapy strategies similarly have had limited success. Multiple deficiencies still exist in our knowledge of this complex disease, and further research is urgently required to overcome these critical issues. This review traces the path undertaken by the different therapeutics assessed in glioblastoma and the impact of precision medicine in this disease. We highlight challenges for precision medicine in glioblastoma, focusing on the issues of tumour heterogeneity, pharmacokinetic-pharmacodynamic optimization and outline the modern hypothesis-testing strategies being undertaken to address these key challenges.
Insights
Precision medicine has advanced solid tumor treatments, but glioblastoma (GBM) remains challenging. Further research is crucial to overcome GBM
Area of Science:
- Neuro-oncology
- Genomics
- Precision Medicine
Background:
- Precision medicine has revolutionized solid tumor treatment by targeting driver mutations.
- Glioblastoma (GBM) shows limited response to targeted agents and immunotherapy despite genomic advances.
- Significant knowledge gaps persist, hindering effective treatment strategies for GBM.
Purpose of the Study:
- To review therapeutic approaches in glioblastoma.
- To evaluate the impact and challenges of precision medicine in GBM.
- To outline strategies for overcoming current therapeutic limitations.
Main Methods:
- Literature review of glioblastoma therapeutics.
- Analysis of precision medicine's role and challenges in GBM.
- Examination of current hypothesis-testing strategies.
Main Results:
- Targeted agents and immunotherapy have shown limited efficacy in clinical trials for GBM.
- Tumor heterogeneity and pharmacokinetic-pharmacodynamic issues present major challenges.
- Novel hypothesis-testing strategies are being developed to address these challenges.
Conclusions:
- Despite advances in precision medicine for other cancers, GBM treatment remains poor.
- Addressing tumor heterogeneity and optimizing drug delivery are critical for improving GBM outcomes.
- Continued research and innovative strategies are urgently needed for effective glioblastoma therapy.
Related Concept Videos
Maslow's Humanistic Approach on Personality
Tumor Immunotherapy
Molecular Models
Personal Identity
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Self-Report Tests of Personality

